Who Supplies Erythromycin to India from CANADA

Importing finished pharmaceutical formulations containing erythromycin into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that both the drug and the manufacturing site be registered. For new drugs, approval under Rule 122E is necessary before applying for registration or import. Applications must be submitted to the Drugs Controller General (India) at CDSCO, FDA Bhawan, Kotla Road, New Delhi.

Imported pharmaceutical formulations must undergo quality testing at CDSCO-approved laboratories. Batch-wise testing is required, with a Certificate of Analysis (CoA) provided for each batch. Stability data must comply with ICH Zone IV guidelines. Products must meet Indian Pharmacopoeia standards. Customs drug inspectors conduct port inspections to verify compliance.

Between 2024 and 2026, the Directorate General of Foreign Trade (DGFT) amended the Standard Input Output Norms (SION) for erythromycin stearate tablets, affecting export processes. However, no significant changes have been reported regarding the import policies for finished erythromycin formulations during this period. (pharmacypro.io)

India imports finished erythromycin formulations to meet domestic demand for branded and patented products, specialized dosage forms, and formulations not produced locally. The market size for erythromycin formulations in India is substantial, with imports playing a crucial role in supplementing domestic production.

The Basic Customs Duty (BCD) for HS Code 30042061 is 10%. An Integrated Goods and Services Tax (IGST) of 12% and a Social Welfare Surcharge (SWS) of 10% are also applicable. There are no exemptions or preferential rates for imports from Canada. The total landed duty percentage is approximately 32%.

India sources finished erythromycin formulations from Canada due to the availability of patented formulations, specialized dosage forms, and high-quality products. Other suppliers include China, Germany, and the United States. Canada's share in the Indian market is modest but significant, offering competitive advantages in quality and innovation.

India imports finished erythromycin formulations from Canada to access patented formulations, specialized dosage forms, and high-quality products not available domestically. Canada's advanced pharmaceutical manufacturing capabilities and adherence to international quality standards make it a preferred source.

Compared to China, the European Union, and the United States, Canada offers competitive advantages in terms of product quality, regulatory compliance, and innovation. While other countries may offer lower prices, Canada's reputation for high-quality and reliable pharmaceutical products justifies the higher cost for Indian importers.

Potential risks include single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. There have been no significant shortages reported in the Canada–India pharmaceutical trade corridor.

1. 1Engage in dual-sourcing strategies to mitigate supply chain risks.
2. 2Implement robust inventory planning to manage lead times and demand fluctuations.
3. 3Establish clear payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Negotiate Minimum Order Quantities (MOQs) that align with demand forecasts.
5. 5Conduct thorough supplier qualification processes to ensure compliance with quality and regulatory standards.

1. 1Obtain Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Register the product with CDSCO using Form 40/41.
3. 3Secure a Drug Import License from the relevant State Drug Controller.
4. 4Obtain a No Objection Certificate (NOC) from the State Drug Controller, if required.
5. 5Engage a licensed customs broker for import clearance.
6. 6Seek an advance ruling for HS Code 30042061, if necessary.

1. 1Certificate of Analysis (CoA) for each batch.
2. 2Certificate of Pharmaceutical Product (CoPP).
3. 3Good Manufacturing Practice (GMP) certificate.
4. 4Drug Master File (DMF) for the product.
5. 5Stability data complying with ICH Zone IVa/IVb guidelines.
6. 6Free Sale Certificate.
7. 7Manufacturer's authorization letter.

CDSCO port inspectors collect samples of imported pharmaceutical formulations for mandatory batch testing. The testing process includes verifying compliance with Indian Pharmacopoeia standards and assessing stability data. If a batch fails testing, it may be rejected, leading to potential delays and additional costs. Common quality issues from Canada include discrepancies in labeling and packaging.

Importers must renew CDSCO registrations annually and comply with periodic audits in Canada. Change control procedures should be in place to manage product modifications. Pharmacovigilance systems must be established for post-import monitoring. Import records must be maintained as per the Drugs and Cosmetics Act for regulatory compliance.